AI tool to guide heart failure medicines compared with usual care
Tests an AI decision support tool for doctors treating adults with reduced-pumping heart failure.
Plain-language title generated from the registry record
Registry title: The Effectiveness and Safety of Artificial Intelligence(AI)-Assisted Medical Treatment Decision Support System Compared to Conventional Care in HFrEF Patients
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Shanghai Zhongshan HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT07380555
- Record updated
- 2 February 2026
- Original description
This clinical trial aims to find out if using an artificial intelligence (AI) decision support system can help doctors better manage medications for people with heart failure with reduced ejection fraction (HFrEF). The main goal is to see if this approach can lower the chance of patients being hospitalized for heart failure or dying from heart-related causes compared to standard care.Read full original descriptionShow less
A Multicenter, Cluster-randomized, Controlled Study Evaluating the Effectiveness and Safety of Artificial Intelligence(AI)-Assisted Medical Treatment Decision Support System Compared to Conventional Care in HFrEF Patients
This clinical trial aims to find out if using an artificial intelligence (AI) decision support system can help doctors better manage medications for people with heart failure with reduced ejection fraction (HFrEF). The main goal is to see if this approach can lower the chance of patients being hospitalized for heart failure or dying from heart-related causes compared to standard care.
About 1,200 participants from 60 hospitals will take part in this study. The hospitals, not the individual patients, are randomly assigned to one of two groups:
AI-Guided Group: Doctors at these hospitals will receive medication recommendations from an AI system based on patient health data.
Standard Care Group: Doctors at these hospitals will manage medications as they normally would, without AI assistance.
All participants will have regular check-ups, both remotely every 30 days and in-person at 3, 6, and 12 months. The study will last about 12 months for each participant.
Inclusion: Age ≥18 years old; Patients diagnosed with HF in hospital and discharged on medical orders; LVEF≤40% detected by echocardiography within 1 month before enrollment; Signed informed consent is obtained.
Exclusion: Patients who are unable or unsuitable for follow-up; Patients with poor compliance, presenting a risk of switching study groups.